Spexis AG
SPEX | SW
Overview
Corporate Details
- ISIN(s):
- CH0106213793
- LEI:
- 391200S8HJE1I96FIG04
- Country:
- Switzerland
- Address:
- Hegenheimermattweg 125, 4123 Allschwil
- Website:
- https://www.polyphor.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Spexis AG is a clinical-stage biopharmaceutical company focused on the discovery and development of treatments for rare diseases and oncology. The company specializes in creating first-in-class macrocyclic molecules. Its therapeutic pipeline includes inhaled murepavadin, a novel-class antibiotic for treating Pseudomonas aeruginosa infections in patients with cystic fibrosis and non-CF bronchiectasis. Another key asset is balixafortide, a macrocyclic CXCR4 inhibitor being evaluated for various oncology indications. Spexis advances its programs through clinical trials and strategic partnerships to bring innovative therapies to patients with high unmet medical needs.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Spexis AG.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2024-11-05 07:15 |
Delisting Announcement
Spexis expects SIX to delist shares of Spexis on the SIX exchange imminently.
|
English | 9.3 KB | |
| 2024-11-05 01:00 |
Delisting Announcement
Spexis expects SIX to delist shares of Spexis on the SIX exchange imminently.
|
English | 7.7 KB | |
| 2024-07-29 07:15 |
Legal Proceedings Report
Spexis granted definitive moratorium status until 25 November 2024, subject to …
|
English | 8.6 KB | |
| 2024-07-29 02:00 |
Legal Proceedings Report
Spexis granted definitive moratorium status until 25 November 2024, subject to …
|
English | 6.9 KB | |
| 2024-07-22 07:15 |
Legal Proceedings Report
Spexis expects that audit of its 2023 financials will not be completed by 31 Ju…
|
English | 10.8 KB | |
| 2024-07-22 02:00 |
Legal Proceedings Report
Spexis expects that audit of its 2023 financials will not be completed by 31 Ju…
|
English | 9.1 KB | |
| 2024-07-08 07:15 |
Legal Proceedings Report
Spexis AG: PARI Pharma GmbH announces termination of ColiFin license to EnBioti…
|
English | 10.0 KB | |
| 2024-07-08 02:00 |
Legal Proceedings Report
Spexis AG: PARI Pharma GmbH announces termination of ColiFin® license to EnBiot…
|
English | 8.4 KB | |
| 2024-06-04 20:00 |
Delisting Announcement
Spexis launches appeal against SIX Exchange Regulation decision to suspend trad…
|
English | 8.0 KB | |
| 2024-06-04 02:00 |
Delisting Announcement
Spexis launches appeal against SIX Exchange Regulation decision to suspend trad…
|
English | 6.4 KB | |
| 2024-05-31 22:00 |
Report Publication Announcement
Spexis receives second extension for the publication of its 2023 annual report …
|
English | 19.4 KB | |
| 2024-05-31 02:00 |
Report Publication Announcement
Spexis receives second extension for the publication of its 2023 annual report …
|
English | 16.6 KB | |
| 2024-04-30 20:30 |
Report Publication Announcement
Spexis receives approval of an extension of the deadline for the publication of…
|
English | 9.8 KB | |
| 2024-04-30 02:00 |
Report Publication Announcement
Spexis receives approval of an extension of the deadline for the publication of…
|
English | 8.2 KB | |
| 2024-04-17 07:15 |
Regulatory News Service
Spexis announces extension of moratorium, receipt of an additional payment rela…
|
English | 13.8 KB |
Automate Your Workflow. Get a real-time feed of all Spexis AG filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Spexis AG via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-06-21 | N/A | Executive member | Other | None | N/A |
